Skip to main content
PharmaEssentia Corporation logo

PharmaEssentia Corporation — Investor Relations & Filings

Ticker · 6446 ISIN · TW0006446008 LEI · 54930001GNQLDIFASK68 TW Manufacturing
Open in API
Filings indexed 36 across all filing types
Latest filing 2026-05-14 Investor Presentation
Country TW Taiwan
Listing TW 6446

About PharmaEssentia Corporation

http://www.PharmaEssentia.com

PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.

Recent filings

Filing Released Lang Actions
115年05月法人說明會簡報 — 644620260514E001.pdf
Investor Presentation Classification · 10% confidence The document is a slide-based presentation (with forward-looking statements and slide numbers) providing a detailed overview of Q1’26 financial performance, strategy, product pipeline, market opportunity, and clinical updates to investors and analysts. This format and content align with an Investor Presentation rather than an actual report filing. Therefore, it is classified as an Investor Presentation (IP).
2026-05-14 English
115年05月法人說明會簡報 — 644620260514M001.pdf
Investor Presentation Classification · 96% confidence The document is a slide-based presentation containing forward‐looking statements, detailed Q1’26 financial highlights (revenue, net profit, EPS, margins), product pipeline updates, market analyses, clinical trial data, and strategic objectives. It is structured as an investor slide deck rather than an annual/quarterly report, press release, or regulatory filing. This matches the definition of an Investor Presentation (IP).
2026-05-14 English
115年05月法人說明會簡報
Regulatory Filings Classification · 75% confidence The document is a short regulatory notice from Taiwan’s public information site listing a company’s institutional investor presentation date, time, location, and links to slide deck PDFs. It does not include substantive financial data or the presentation content itself—only an announcement with attachments. This does not fit the detailed Investor Presentation category (which requires the presentation content) and is best classified as a general regulatory filing announcement.
2026-05-14 Chinese
115年第1季財務報告書 — 202601_6446_AI1.pdf
Interim / Quarterly Report Classification · 96% confidence The document is a consolidated financial report for the three‐month periods ended March 31 (Interim periods), including auditor’s review (EY), detailed balance sheet, income statement, cash flow statement, and extensive notes under IFRS 34 “Interim Financial Reporting.” It is not merely an announcement or summary but the full interim financial statements. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-14 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 85% confidence The document is a Q1 filing (“115年1季申報作業”) on Taiwan’s MOPS platform for a listed company, containing actual interim financial data (investment balances, equity method results) rather than just an announcement or link to a report. This fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-13 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure (公開資訊觀測站) by a Taiwan‐listed company detailing its direct and indirect investments in Mainland China for the period (年度115, 季別01). It is a specific compliance table of cross‐strait investment amounts, approved limits, repatriated gains, etc. There are no full financial statements, narrative MD&A or earnings highlights—just a compliance schedule. This falls under general regulatory filings rather than a standalone financial report, presentation, or management notice. Therefore it should be classified as Regulatory Filings (RNS).
2026-05-13 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.